Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

FTE Network (FTNW) – A Unique Opportunity for Explosive Growth

The expansion in data usage and communications has continued to inflate beyond all predictions, with networks rapidly being pushed far beyond originally anticipated requirements. The unparalleled growth is expected to continue as developing technologies challenge existing capabilities, creating an unprecedented demand for improved network infrastructures and associated services. Florida-based FTE Networks (OTCQX: FTNW) has grown […]

Moxian, Inc. (MOXC) – Facilitating Stronger Customer Relationships

Keeping and cultivating satisfied customers is clearly a critical aspect of any company’s success. Building and maintaining strong customer relationships is key, requiring businesses to not only stay in touch with customers, but also to effectively deal with any customer service issues. The most successful businesses have been known to build the most impressive records […]

Aerie Pharmaceuticals (AERI) Eyeing Innovative Glaucoma and Ocular Hypertension Therapies

Aerie Pharmaceuticals. Inc. (NASDAQ: AERI) is a publicly traded clinical stage pharmaceutical company focusing on the discovery of innovative treatments for glaucoma and other eye ailments. Its leading product candidates, Rhopressa™ and Roclatan™, are believed to be effective for most glaucoma patients, based on clinical trials results, and are currently in different stages of development […]

Soligenix, Inc. (SNGX) Late-Stage Biopharma with Bedrock Funding Primed for Commercial Success, Ready to Uplist to NASDAQ

For a late-stage rare diseases focused boipharma innovator like Soligenix (OTCQB: SNGX), with up to $58 million of support for its Vaccines/BioDefense segment coming directly from NIAID contract funding (National Institute of Allergy and Infectious Diseases, a division of the NIH), recent news about the success of its BioTherapeutics segment is propitiously timed, amid the […]

 

From Our Blog

Brera Holdings PLC (NASDAQ: BREA) Offers Investors a New Path to Pro Sports Ownership

July 17, 2025

Brera Holdings (NASDAQ: BREA), an Ireland-based international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) strategy, is tapping two converging trends reshaping professional sports ownership: the influx of capital from private family offices and the rising demand for democratized access to sports as an […]

Rotate your device 90° to view site.